# GenBody

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/genbody

- Industry: Biotechnology
- Headquarters: Cheonan-si, South Korea
- Website: www.genbody.co.kr
- Total disclosed funding: $4.2M
- Latest round: Series B (Dec 20, 2016)
- Investors on record: 3

## About

Based in Cheongju, South Korea, and founded in 2012, GenBody Inc. operates as a biotechnology company that creates innovative technologies for the development of raw materials for diagnostic use. The company possessed patented technologies including fluorescent immuno-diagnostics. In October 2015, the company established a branch office in China. The company also obtained ISO13485 certification. In March 2026, unspecified investors acquired a stake in GenBody Inc. from AJU IB Investment. Financial terms were not disclosed.

The company offers diagnostic total solution such as rapid diagnostic tests (RDTs), fluorescent immuno-diagnostic tests, ELISA, molecular diagnostic tests (MDx) and clinical chemistry. Products within include Zika IgG/IgM, Yellow fever NS1 Antigen, Helicosign Dry, DOA 5 (THC/MET/MOR/AMP/BZO), GenBody Influenza/COVID-19 Ag Multi and COVID-19 Ag. The company also provides veterinary products.

## Funding rounds

- Series B, Dec 20, 2016, $4.2M — AJU IB Investment, Korea Technology Finance Corporation, BNH Investment

## Investors

- AJU IB Investment (https://capitalatlas.ai/funds/aju-ib-investment) — Series B
- Korea Technology Finance Corporation — Series B
- BNH Investment (https://capitalatlas.ai/funds/bnh-investment) — Series B